Keywords
rectal carrying
surveillance
control measures
How to Cite
Abstract
Monitoring the rectal carrying of carbapenemase-producing bacilli (PR-BPC) allows knowing the impact of infection control measures. Objective: To assess the effectiveness of the control measures applied in the adult intensive care unit of a hospital in suburban Buenos Aires, Argentina. Materials and methods: A prospective cohort study was conducted before (PI) and after (PP) the implementation of the control measures in the Adult Intensive Care Unit of the hospital. For 4 months, 155 rectal swabs from 97 patients (PP) were studied by multiplex PCR (BD MaxTM System, Becton Dickinson, USA) and phenotypic tests were performed. Results: PR-BPC was 48% in both periods. The prevalent carbapenemase was NDM and increased from 40.4% to 59.1% in PP (p<0.05). In each cohort, 25% of the carrier patients had a subsequent infection with carbapenemase-producing bacilli. Conclusion: The fact that PR-BPC was similar in both periods suggests that the control measures did not have the expected impact.
References
1. Campos-Madueno EI, Moradi M, Eddoubaji Y, Shahi F, Moradi S, Bernasconi OJ, et al. Intestinal colonization with multidrug-resistant Enterobacterales: screening, epidemiology, clinical impact, and strategies to decolonize carriers. Eur J Clin Microbiol Infect Dis. 2023;42(3):229-254, https://doi.org/10.1007/s10096-023-04548-2
2. Yan L, Sun J, Xu X, Huang S. Epidemiology and risk factors of rectal colonization of carbapenemase-producing Enterobacteriaceae among high-risk patients from ICU and HSCT wards in a university hospital. Antimicrob Resist Infect Control. 2020;9(1):155, https://doi.org/10.1186/s13756-020-00816-4
3. Tălăpan D, Rafila A. Five-Year Survey of Asymptomatic Colonization with Multidrug- Resistant Organisms in a Romanian Tertiary Care Hospital. Infect Drug Resist. 2022;15: 2959-2967, https://doi.org/10.2147/idr.s360048 4. Callejón Fernández M, Madueño Alonso A, Abreu Rodríguez R, Aguirre-Jaime A, Castro Hernández MB, Ramos-Real MJ, et al. Risk factors for colonization by carbapenemase-producing bacteria in Spanish long-term care facilities: a multicentre point-prevalence study. Antimicrob Resist Infect Control. 2022;11(1):163, https://doi.org/10.1186/s13756-022-01200-0
5. Nicola F, Cejas D, González-Espinosa F, Relloso S, Herrera F, Bonvehí P, et al. Outbreak of Klebsiella pneumoniae ST11 Resistant To Ceftazidime-Avibactam Producing KPC-31 and the Novel Variant KPC-115 during COVID-19 Pandemic in Argentina. Microbiol Spectr. 2022;10(6):e0373322, https://doi.org/10.1128/spectrum.03733-22
6. Togneri A. M, Pérez M, Pérez Catalán S, Bastanza A, Re W, Gañete M, et al. Vigilancia activa de la portación de bacilos productores de carbapenemasas por PCR múltiple en tiempo real. Experiencia a cuatro meses de su implementación. ByPC. 2024;88(2):15-19, https://doi.org/10.62073/bypc.v88i2.234
7. Tacconelli E, Cataldo MA, Dancer SJ, De Angelis G, Falcone M, Frank U, et al. European Society of Clinical Microbiology. ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrugresistant Gram-negative bacteria in hospitalized patients. Clin Microbiol Infect. 2014;20Suppl1:1-55, https://doi.org/10.1111/1469-0691.12427
8. Barcelona L, Pagano I, Sued O, Reina R, Andión E, Almuzara M, Sudano D. Documento de Consenso Interinstitucional. Estrategia Multimodal de Intervención- Febrero 2021. Disponible en: https://www.sati.org.ar/consenso-interinstitucional- estrategia-multimodal-de-intervencion-2021. [Fecha de consulta: enero del 2022]
9. Girlich D, Oueslati S, Bernabeu S, Langlois I, Begasse C, Arangia N, et. al. Evaluation of the BD MAX Check-Points CPO Assay for the Detection of Carbapenemase Producers Directly from Rectal Swabs. J Mol Diagn. 2020;22(2):294-300, https://doi.org/10.1016/j.jmoldx.2019.10.004
10. Programa Nacional de Control de Calidad en Bacteriología. INEI-ANLIS “Dr. Carlos G. Malbrán”. Alerta epidemiológica emergencia de Enterobacterales doble productores de carbapenemasas. Boletín Informativo nro. 4 - abril 2021. Disponible en http://antimicrobianos.com.ar/ATB/wp-content/uploads/2021/05/Alerta-epidemiol%C3%B3gica-dobles-productores-de-carbapenemasa-COVID-
19-v4.pdf [Fecha de consulta julio de 2023].
11. Caliskan-Aydogan O, Alocilja EC. A Review of Carbapenem Resistance in Enterobacterales and Its Detection Techniques. Microorganisms. 2023;11(6):1491, https://doi.org/10.3390/microorganisms11061491
12. Bush K, Jacoby GA. Updated functional classification of beta-lactamases. Antimicrob Agents Chemother. 2010;54(3):969-76, https://doi.org/10.1128/aac.01009-09
13. Escandón-Vargas K, Reyes S, Gutiérrez S, Villegas MV. The epidemiology of carbapenemases in Latin America and the Caribbean. Expert Rev Anti Infect Ther. 2017;15(3):277-297, https://doi.org/10.1080/14787210.2017.1268918